Description
Apnat (apalutamide) is a generic version of medicine, used for the treatment of two types of prostate cancer in adult men.
- Metastatic Castration-sensitive Prostate Cancer (mCSPC): This type of prostate cancer has spread to other parts of the body and still responds to a medical or surgical treatment that reduces testosterone
- Non-metastatic Castration-resistant Prostate Cancer (nmCRPC): This type of prostate cancer has not spread to other parts of the body and no longer responds to a medical or surgical treatment that reduces testosterone.
Apnat (apalutamide) comes as a tablet. It is available in 60 mg strength. The recommended dose of apalutamide for mCSPC or nmCRPC is 240 mg (four 60 mg tablets). Take 4 tablets of apalutamide once a day (either in the morning or at night) orally with or without food, as directed by a health specialist. Do not chew, crush, or split apalutamide tablets, but swallow whole.
Patients should also receive gonadotropin-releasing hormone (GnRH) analog concurrently or should have had a bilateral orchiectomy.
If you missed a dose of Apnat, take your next scheduled dose as soon as possible. In case you missed any dose for a whole day, just take your normal/regular dose the very next day.
Side Effects:The most commonly reported apnat (apalutamide) side effects are:
- fall
- fatigue
- arthralgia
- rash
- hypertension
- hot flush
- diarrhea
- fracture
- weight decreased
- decreased appetite
- Ischemic cardiovascular events occurred in those receiving Erleada. Assess for signs/symptoms of ischemic heart complications. Optimize management of cardiovascular risk factors.
- Fractures occurred in those receiving Apnat 60 mg tablet. Assess patients for fracture risk and treat them with bone-targeted agents as per established guidelines.
- Falls occurred in those receiving Apalutamide with increased incidence in the elderly. Evaluate all the patients for fall risk.
- Seizure occurred in roughly 0.4 percent of patients receiving apalutamide (erleada). Permanently discontinue this treatment in those who develop a seizure during treatment.
- The medicine apalutamide 60 mg can be responsible for causing fetal harm. Advise males with female partners of reproductive age/potential to use appropriate contraception.
